Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
age-related macular degeneration
Biotech
AlloVir finds new identity via eye disease biotech merger
The all-stock transaction will create a combined company operating under the Kalaris brand and focused on Kalaris’ anti-VEGF drug.
James Waldron
Nov 8, 2024 9:05am
FDA clears first treatment for dry AMD, with LumiThera's Valeda
Nov 6, 2024 10:30am
Ionis axes eye disease from targets of Roche-partnered prospect
Aug 1, 2024 8:06am
Innovent's anti-VEGF drug matches Eylea in eye disease trial
Mar 19, 2024 10:36am
RetinAI Medical joins non-profit macular degeneration initiative
Nov 29, 2023 11:36am
'Unexpected' cataracts in ph. 3 end Kodiak's hopes for eye drug
Jul 24, 2023 8:58am
